BBIO's Quality Score fell 2 points on Mon, Nov 2, to 7.
Follow BBIO's trial news. Pro members can get an alert when BridgeBio Pharma files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 6% on Oct 30 while the S&P 500 fell 2%.
“The $232.5 million increase was primarily driven by a $145.2 million increase in Attruby net product revenue”
| The company | Sales up 202% on the year |
| Latest filing | 8-K, Oct 29 |
Expected to report Tue Feb 23, after the close
About 6 quarters
CEO Neil Kumar sold 10,000 shares on Sep 17, under a planned sale. 25 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
BBIO is #53 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 53 |
Share count against a year before: BBIO +2.8%, TNGX +36%, SRPT +7.6%, TVTX +5.1%.
Expected to report Tue Feb 23, after the close (in 113 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $353.2M, 193% more than a year ago; a loss of $0.42 a share, from $0.95.
“The $232.5 million increase was primarily driven by a $145.2 million increase in Attruby net product revenue, a $71.1 million increase in license and services revenue primarily due to recognition of a $75.0 million sales milestone under the Bayer License Agreement achieved during the third quarter of 2026, and a $16.2 million increase in royalty revenue primarily earned from net product sales of BEYONTTRA in the EU and Japan.”
BBIO's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The $443.5 million increase was primarily driven by a $440.0 million increase in Attruby net product revenue and a $39.3 million increase in royalty revenue primarily earned from net product sales of BEYONTTRA in the EU and Japan.”
From its results filing (SEC filing · Oct 29)
Sales grew 86% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 10% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | +3.0% | +6.0% | open |
| Aug 10, 2026 | +2.8% | -1.1% | -5.7% |
| May 7, 2026 | -1.4% | -0.1% | +3.3% |
Sales grew in four of the last six years, to $502M in 2025. It lost money in each of the seven years.
4 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BBIO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
“The biopharmaceutical industry is highly competitive, and we face competition from established pharmaceutical and biotechnology companies, as well as academic research institutions, developing therapies for similar indications.”
BBIO scores 7 today, which Breakaway calls Average. It is #53 of 291 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 6% on Oct 30 while the S&P 500 fell 2%. Cash lasts about 6 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BBIO scores 7 today, which Breakaway calls Average (6 to 10). That is #53 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BBIO's 7.
Expected to report Tue Feb 23, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BBIO closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.